Highlights HTG Molecular Diagnostics, Inc.

Equities

HTGMQ

US40434H3021

Delayed OTC Markets Other stock markets 11:15:07 2024-05-15 am EDT			5-day change	1st Jan Change
0.0025 ^USD	0.00%		+66.67%	+92.31%

2023	Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc.	CI
2023	Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HTG Molecular Diagnostics, Inc. to Highlight the Advantages of its Drug Discovery Engine at the 2023 Biotechnology Innovation Organization	23-05-18	CI
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
HTG Molecular Diagnostics, Inc. Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event	23-01-09	CI
HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022	23-01-06	CI
HTG Molecular Diagnostics to Begin Trading on Split-Adjusted Basis on Wednesday	22-12-20	MT
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
HTG Molecular Diagnostics, Inc. to Collaborate With OmiCure, Providing Transcriptomic Data Across Several Cancer Indications	22-10-26	CI
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
HTG Molecular Diagnostics, Inc. Releases Second Whitepaper for Its Transcriptome-Informed Approach to Drug Discovery	22-07-06	CI
HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2022	22-05-12	CI
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
HTG Molecular Diagnostics, Inc. Expands Features of Proprietary HTG EdgeSeq Technology	22-04-06	CI
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for the Full Year 2021	22-01-06	CI
HTG Molecular Diagnostics, Inc. Completes HTP Product Next-Phase Development Milestone	21-12-22	CI
HTG Molecular Diagnostics, Icahn Mount Sinai Enter Bladder Cancer Research Collaboration	21-11-17	MT
HTG Molecular Diagnostics, Inc. and Icahn School of Medicine at Mount Sinai Announce Bladder Cancer Research Collaboration	21-11-17	CI
HTG Molecular Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
HTG Molecular Diagnostics, Inc. Enters into Third and Fourth Amendment to Its Standard Commercial-Industrial Multi Tenant Triple Net Lease with Pegasus Properties L.P	21-09-29	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights HTG Molecular Diagnostics, Inc.

Equities

HTGMQ

US40434H3021

Highlights

Filters